Tumor Associated Stromal Cells Play a Critical Role on the Outcome of the Oncolytic Efficacy of Conditionally Replicative Adenoviruses

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Lopez, M Verónica ^a   Viale, Diego L ^a   Cafferata, Eduardo G A ^a   Bravo, Alicia I ^b   Carbone, Cecilia ^c   Gould, David ^d   Chernajovsky, Yuti ^d   Podhajcer, Osvaldo L ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b Hospital Eva Peron   (Argentina)

^c UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEONECTIN;

ADENOVIRUS; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL LINE; CYTOPATHOGENIC EFFECT; GENETICS; HUMAN; MOUSE; NEOPLASM; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; STROMA CELL; TUMOR CELL LINE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CELL LINE; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; OSTEONECTIN; PROMOTER REGIONS, GENETIC; STROMAL CELLS; VIRUS REPLICATION;

EID: 66849134484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005119     Document Type: Article

References (61)

1. Albini A, Sporn MB, (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7: 139-147.
2. Sugimoto H, Mundel TM, Kieran MW, Kalluri R, (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5: 1640-1646.
3. Ronnov-Jessen L, Petersen OW, Bissell MJ, (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76: 69-125.
4. Chlenski A, Guerrero LJ, Yang Q, Tian Y, Peddinti R, et al.(2007) SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene 26: 4513-4522.
5. Kalluri R, Zeisberg M, (2006) Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
6. Marx J, (2008) Cancer biology. All in the stroma: cancer's Cosa Nostra. Science 320: 38-41.
7. Waehler R, Russell SJ, Curiel DT, (2007) Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587.
8. Hedley SJ, Chen J, Mountz JD, Li J, Curiel DT, et al.(2006) Targeted and shielded adenovectors for cancer therapy. Cancer Immunol Immunother.
9. Alemany R, (2007) Cancer selective adenoviruses. Mol Aspects Med 28: 42-58.
10. Mathis JM, Stoff-Khalili MA, Curiel DT, (2005) Oncolytic adenoviruses- selective retargeting to tumor cells. Oncogene 24: 7775-7791.
11. Mok W, Boucher Y, Jain RK, (2007) Matrix metalloproteinases-1 and-8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 67: 10664-10668.
12. Clark CJ, Sage EH, (2008) A prototypic matricellular protein in the tumor microenvironment-Where there's SPARC, there's fire. J Cell Biochem.
13. Bradshaw AD, Sage EH, (2001) SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107: 1049-1054.
14. Vernon RB, Lane TF, Angello JC, Sage H, (1991) Adhesion, shape, proliferation, and gene expression of mouse Leydig cells are influenced by extracellular matrix in vitro. Biol Reprod 44: 157-170.
15. Yan Q, Sage EH, (1999) SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 47: 1495-1506.
16. Podhajcer OL, Benedetti L, Girotti MR, Prada F, Salvatierra E, et al.(2008) The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev.
17. Yan Q, Sage EH, (1999) SPARC, a Matricellular Glycoprotein with Important Biological Functions. Journal of Histochemistry and Cytochemistry 47: 1495-1506.
18. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, et al.(1997) Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3: 171-176.
19. Rempel SA, Golembieski WA, Fisher JL, Maile M, Nakeff A, (2001) SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol 53: 149-160.
20. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL, (2000) Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 6: 1140-1149.
21. Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, et al.(2004) Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem 279: 52200-52209.
22. Lane TF, Sage EH, (1994) The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB Journal 8: 163-173.
23. Ledda MF, Bravo AI, Adris S, Bover L, Mordoh J, et al.(1997) The expression on the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. Journal of Investigative Dermatology 108: 210-214.
24. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, et al.(1995) Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 64: 70-75.
25. Porte H, Triboulet JP, Kotelevets L, Carrat F, Prevot S, et al.(1998) Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 4: 1375-1382.
26. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, et al.(2003) SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22: 5021-5030.
27. Bellahcene A, Castronovo V, (1995) Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146: 95-100.
28. Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, et al.(2003) Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 63: 5376-5380.
29. Rempel SA, Ge S, Gutierrez JA, (1999) SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 5: 237-241.
30. Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, et al.(2001) Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 166: 2495-2499.
31. Sakai N, Baba M, Nagasima Y, Kato Y, Hirai K, et al.(2001) SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. Hum Pathol 32: 1064-1070.
32. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, et al.(1997) The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108: 210-214.
33. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, et al.(2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25: 319-325.
34. Kato Y, Lewalle J-M, Baba Y, Tsukuda M, Sakai N, et al.(2001) Induction of SPARC by VEGF in Human Vascular Endothelial Cells. Biochemical and Biophysical Research Communications 287: 422-426.
35. Hafner M, Zimmermann K, Pottgiesser J, Krieg T, Nischt R, (1995) A purine-rich sequence in the human BM-40 gene promoter region is a prerequisite for maximum transcription. Matrix Biol 14: 733-741.
36. Dominguez P, Ibaraki K, Robey PG, Hefferan TE, Termine JD, et al.(1991) Expression of the osteonectin gene potentially controlled by multiple cis- and trans-acting factors in cultured bone cells. J Bone Miner Res 6: 1127-1136.
37. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ, (2002) Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 21: 7077-7091.
38. Lopez MV, Blanco P, Viale DL, Cafferata EG, Carbone C, et al.(2006) Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth. Mol Cancer Ther 5: 2503-2511.
39. Kadonaga JT, (2002) The DPE, a core promoter element for transcription by RNA polymerase II. Exp Mol Med 34: 259-264.
40. Martin-Duque P, Jezzard S, Kaftansis L, Vassaux G, (2004) Direct comparison of the insulating properties of two genetic elements in an adenoviral vector containing two different expression cassettes. Hum Gene Ther 15: 995-1002.
41. Gonzalez R, Huang W, Finnen R, Bragg C, Flint SJ, (2006) Adenovirus E1B 55-kilodalton protein is required for both regulation of mRNA export and efficient entry into the late phase of infection in normal human fibroblasts. J Virol 80: 964-974.
42. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE, (2007) Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216.
43. Hodge LD, Scharff MD, (1969) Effect of adenovirus on host cell DNA synthesis in synchronized cells. Virology 37: 554-564.
44. Goodrum FD, Ornelles DA, (1997) The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J Virol 71: 548-561.
45. Fisher K, (2006) Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther 8: 301-313.
46. Bilbao R, Bustos M, Alzuguren P, Pajares MJ, Drozdzik M, et al.(2000) A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther 7: 1824-1832.
47. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, et al.(2006) Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 98: 1482-1493.
48. Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, et al.(2003) Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 125: 1203-1218.
49. Selden C, Mellor N, Rees M, Laurson J, Kirwan M, et al.(2007) Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. J Gene Med 9: 67-76.
50. Sage H, Vernon RB, Decker J, Funk S, Iruela-Arispe ML, (1989) Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J Histochem Cytochem 37: 819-829.
51. Gros A, Martinez-Quintanilla J, Puig C, Guedan S, Mollevi DG, et al.(2008) Bioselection of a Gain of Function Mutation that Enhances Adenovirus 5 Release and Improves Its Antitumoral Potency. Cancer Res 68: 8928-8937.
52. Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, et al.(2004) Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 11: 1694-1702.
53. Volk AL, Rivera AA, Kanerva A, Bauerschmitz G, Dmitriev I, et al.(2003) Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther 2: 511-515.
54. Nettelbeck DM, Rivera AA, Kupsch J, Dieckmann D, Douglas JT, et al.(2004) Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer 108: 136-145.
55. Savontaus MJ, Sauter BV, Huang TG, Woo SL, (2002) Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther 9: 972-979.
56. Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, et al.(2003) An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 63: 1490-1499.
57. Bett AJ, Haddara W, Prevec L, Graham FL, (1994) An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 91: 8802-8806.
58. Lieber A, He CY, Kirillova I, Kay MA, (1996) Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 70: 8944-8960.
59. Denizot F, Lang R, (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89: 271-277.
60. Sova P, Ren XW, Ni S, Bernt KM, Mi J, et al.(2004) A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 9: 496-509.
61. Petersen S, Thames HD, Nieder C, Petersen C, Baumann M, (2001) The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis Colon Rectum 44: 322-333; discussion 333-324.